IQV IQVIA
Data-plus-CRO franchise worth owning, but leverage and full pricing leave little margin of safety.
The story
IQVIA pairs the largest contract research organization with a proprietary real-world healthcare data and analytics franchise, a combination rivals find hard to copy and that makes it the default partner for large pharma. It is a mature compounder: mid-single-digit organic growth with operating leverage. Reported margins are held down by roughly 6 points of amortization from the Quintiles-IMS merger. Revenue reaccelerated to about 6% TTM as the biotech funding slump and trial cancellations eased, though leverage stays high at about $13.7B of net debt.
Growth y1 rises slightly to 6% because TTM revenue grew 6.1% (16.31B to 17.31B). Margin stays near 20% as amortization rolls off and cash-margin economics show through. I made two material moves because my prior value sat more than 50% below a heavily covered price. Sales-to-capital goes from 1.6 to 2.0 because the reported 0.78 is inflated by merger goodwill, while organic growth needs little capital (capex is about 3.8% of revenue). The horizon goes from 8 to 10 years because the data moat and outsourcing penetration give a longer runway than a typical services firm.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 20.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.00 |
| Beta | 1.00 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 18.76B |
| PV of terminal value | 20.83B |
| Equity value | 25.21B |
| ÷ shares → per share | $152.97 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 18.35B | 6.0% | 14.8% | 2.29B | 519.33M | 1.77B | 1.62B |
| 2 | 19.39B | 5.7% | 16.1% | 2.63B | 519.91M | 2.11B | 1.77B |
| 3 | 20.42B | 5.3% | 17.4% | 2.99B | 517.05M | 2.47B | 1.90B |
| 4 | 21.44B | 5.0% | 18.7% | 3.37B | 510.59M | 2.86B | 2.01B |
| 5 | 22.45B | 4.7% | 20.0% | 3.78B | 500.38M | 3.28B | 2.11B |
| 6 | 23.42B | 4.3% | 20.0% | 3.94B | 486.32M | 3.46B | 2.03B |
| 7 | 24.35B | 4.0% | 20.0% | 4.10B | 468.36M | 3.63B | 1.96B |
| 8 | 25.25B | 3.7% | 20.0% | 4.25B | 446.51M | 3.80B | 1.88B |
| 9 | 26.09B | 3.3% | 20.0% | 4.39B | 420.80M | 3.97B | 1.79B |
| 10 | 26.87B | 3.0% | 20.0% | 4.52B | 391.34M | 4.13B | 1.71B |
Key risks
- Biotech funding or big-pharma pipeline cuts lead to more trial cancellations and slower bookings
- High leverage (about $13.7B net debt) makes equity value sensitive to rates and refinancing
- AI-driven trial design and in-house analytics erode pricing power in the TAS and commercial data segments
Catalysts
- Book-to-bill sustained above 1.15x, turning backlog into accelerating revenue
- Acquired-intangible amortization rolls off, lifting GAAP margins toward cash economics, with buybacks shrinking the share count